Coronavirus vaccine can train immune system, says US vaccine producer
Work on a coronavirus vaccine has been taking place at unprecedented speed, with around 80 groups around the world working on them. Moderna was the first to test an experimental vaccine
Coronavirus vaccine will be able to train people's immune system to fight coronavirus, such a claim has been made by vaccine producer in the US.
Moderna, the vaccine producing company said neutralising antibodies were found in the first eight people who took part in their safety trials, reports BBC.
It also said the immune response was similar to people infected with the actual virus.
Keep updated, follow The Business Standard's Google news channel
The study is known as a phase 1 trial as it is designed to test whether the vaccine is safe, rather then whether it is effective.
Larger trials to see whether the jab actually protects against infection are expected to start in July.
Work on a coronavirus vaccine has been taking place at unprecedented speed, with around 80 groups around the world working on them. Moderna was the first to test an experimental vaccine, called mRNA-1273, in people.
The vaccine is a small snippet of the coronavirus's genetic code, which is injected into the patient.
It is not capable of causing an infection or the symptoms of Covid-19, but is enough to provoke a response from the immune system.
The vaccine trials, run by the US government's National Institute of Allergy and Infectious Diseases, showed the vaccine led to the production of antibodies which can neutralise the coronavirus.
However, testing for these neutralising antibodies has only taken place on the first eight, out of 45, people on the trial.
The people on the trial were taking either a low, middle or high dose. The highest dose was linked to most side-effects.
However, Moderna said that even people taking the lowest dose had antibodies at the same levels seen in patients who recover from Covid-19.
And antibodies "significantly exceeded" those in recovered patients for people on the middle dose.
It will take larger trials to see if people are protected against the virus. However, experiments on mice showed the vaccine could prevent the virus replicating in their lungs.
"These interim phase 1 data, while early, demonstrate that vaccination with mRNA-1273 elicits an immune response of the magnitude caused by natural infection," said Dr Tal Zaks, chief medical officer at Moderna.
"These data substantiate our belief that mRNA-1273 has the potential to prevent Covid-19 disease and advance our ability to select a dose for pivotal trials."
Moderna said it was hoping to start a large-scale trial in July, and that it was already investigating how to manufacture the vaccine at scale.
